"Interferon-beta" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the type I interferons produced by fibroblasts in response to stimulation by live or inactivated virus or by double-stranded RNA. It is a cytokine with antiviral, antiproliferative, and immunomodulating activity.
| Descriptor ID |
D016899
|
| MeSH Number(s) |
D12.644.276.374.440.890.275 D12.776.467.374.440.890.275 D23.529.374.440.890.275
|
| Concept/Terms |
Interferon-beta- Interferon-beta
- Interferon beta
- Interferon, Fibroblast
- Fibroblast Interferon
- Interferon, beta
- beta Interferon
- beta-Interferon
beta-1 Interferon- beta-1 Interferon
- beta 1 Interferon
- Interferon-beta1
- Interferon beta1
- Interferon, beta-1
- Interferon, beta 1
|
Below are MeSH descriptors whose meaning is more general than "Interferon-beta".
Below are MeSH descriptors whose meaning is more specific than "Interferon-beta".
This graph shows the total number of publications written about "Interferon-beta" by people in this website by year, and whether "Interferon-beta" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 2 | 0 | 2 |
| 2000 | 2 | 0 | 2 |
| 2001 | 2 | 1 | 3 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 2 | 0 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 1 | 3 |
| 2010 | 3 | 3 | 6 |
| 2011 | 2 | 1 | 3 |
| 2012 | 3 | 3 | 6 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interferon-beta" by people in Profiles.
-
Evaluating Efficacy Outcomes in Pediatric Multiple Sclerosis Patients While Using Avonex or Plegridy via USNPMSC Registry. J Child Neurol. 2026 Apr; 41(4):545-555.
-
Type I interferon limits central nervous system autoimmunity by modulating the microRNA-21-FOXO1 axis in pathogenic T helper 17 cells. Sci Transl Med. 2025 Sep 10; 17(815):eadp5802.
-
Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. J Clin Invest. 2020 04 01; 130(4):1912-1930.
-
Relapse recovery: The forgotten variable in multiple sclerosis clinical trials. Neurol Neuroimmunol Neuroinflamm. 2020 03; 7(2).
-
A pharmacogenetic study implicates NINJ2 in the response to Interferon-? in multiple sclerosis. Mult Scler. 2020 08; 26(9):1074-1082.
-
An Immunocompetent Mouse Model of Zika Virus Infection. Cell Host Microbe. 2018 05 09; 23(5):672-685.e6.
-
The Complement Anaphylatoxins C5a and C3a Suppress IFN-? Production in Response to Listeria monocytogenes by Inhibition of the Cyclic Dinucleotide-Activated Cytosolic Surveillance Pathway. J Immunol. 2017 04 15; 198(8):3237-3244.
-
Protease-Activated Receptor 1 Enhances Poly I:C Induction of the Antiviral Response in Macrophages and Mice. J Innate Immun. 2017; 9(2):181-192.
-
A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity. Ann Neurol. 2015 Jul; 78(1):115-27.
-
Transcriptional repression of IFN?1 by ATF2 confers melanoma resistance to therapy. Oncogene. 2015 Nov 12; 34(46):5739-48.